The Nanosonics Story

Nanosonics is leading the way with innovative solutions focused on preventing the transmission of life-altering infections.

Nanosonics is an Australian infection prevention company that has successfully developed and commercialised a unique automated disinfection technology, the trophon® device, representing the first major innovation in high level disinfection for ultrasound probes in more than 20 years. The trophon device is fast becoming the global standard of care for ultrasound probe disinfection.

Preventable infections are exactly that - preventable. But many medical institutions are forced to spend time and resources dealing with outbreaks of preventable infections. These infections diminish a patient's quality of care and undermine a healthcare professional's capacity to provide this care.

For this reason Nanosonics constantly pursues breakthrough innovations with the potential to transform infection prevention. Our vision is to provide fail-safe infection prevention solutions that protect not only an institution's quality of care, but more importantly the lives of those they treat.

So we pioneer ground-breaking technologies to prevent life-altering infections. We set new standards that redefine best practice. And we strive to be a global leader in infection prevention innovation.

OUR MISSION: We improve the safety of patients, clinics, their staff and the environment by transforming the way infection prevention practices are understood and conducted, and introducing innovative technologies that deliver improved standards of care.

Our Core Values


Our 5 Areas Of Focus


Company Timeline

Founded in 2001, Nanosonics is headquartered in Sydney, Australia.

Nanosonics lists on the Australian Securities Exchange (NAN) in 2007.

In 2009, Nanosonics launched the trophon EPR device, featuring our unique, automated solution for the HLD of intracavity and surface ultrasound probes.

In 2011, Nanosonics launched the trophon EPR device throughout North America, in a strategic partnership with GE Healthcare.

IN MARCH 2015, Nanosonics was included in the Australian Stock Exchange ASX300 Index (Australia’s top 300 companies by market capitalization). 

The company joined the Australian Stock Exchange ASX200 Index (Australia’s top 200 companies by market capitalization).

IN AUGUST 2018, Nanosonics launched the trophon®2 device, the latest innovation in ultrasound probe high level disinfection. We also launched trophon® Companion Wipes, the perfect partner to streamline ultrasound probe reprocessing.

In 2021, Nanosonics introduced Nanosonics AuditProTM, which when deployed with the trophon2 device, standardizes infection control workflow compliance management.

In February 2022, Nanosonics hit a milestone of more than 25,000 trophon devices installed throughout North America, translating to patients protected in more than 100 million procedures.


Our Global Presence

Next
Careers